Inhibitor Therapeutics (INTI) Enterprise Value Growth (1y) (2013 - 2026)
Inhibitor Therapeutics (INTI) Enterprise Value Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.13% |
| Dec 31, 2025 | 57.63% |
| Sep 30, 2025 | 53.13% |
| Jun 30, 2025 | 47.88% |
| Mar 31, 2025 | 43.74% |
| Dec 31, 2024 | 36.57% |
| Sep 30, 2024 | 32.90% |
| Jun 30, 2024 | 29.72% |
| Mar 31, 2024 | 28.76% |
| Dec 31, 2023 | 26.03% |
| Sep 30, 2023 | -17,875.83% |
| Jun 30, 2023 | -40,390.39% |
| Mar 31, 2023 | -29,492.57% |
| Dec 31, 2022 | -38,923.13% |
| Sep 30, 2022 | 0.43% |
| Jun 30, 2022 | 75.06% |
| Mar 31, 2022 | 56.72% |
| Dec 31, 2021 | 59.20% |
| Sep 30, 2021 | -45.17% |
| Jun 30, 2021 | 27.18% |